NEW DELHI -- Biocon Biologics, a unit of India's largest biopharmaceutical company Biocon, is in talks with Asia-focused Baring Private Equity Asia to raise funding in lieu of a minority stake, sources familiar with the matter told DealStreetAsia.
DealStreetAsia
India's Biocon Biologics in funding talks with Baring PE Asia
Country's largest biopharmaceutical eyes valuation of over $100m
.jpg?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
Biocon Biologics offers treatment for chronic and acute diseases, including diabetes, oncology, nephrology and cancer.
Read Next
Latest on DealStreetAsia
